Literature DB >> 23459000

The Utility of 3D Ultramicroscopy for Evaluating Cellular Therapies After Spinal Cord Injury.

M Ghosh1, N Jährling, M C Henao, H-U Dodt, D D Pearse.   

Abstract

Cell therapies have shown promise for repairing the injured spinal cord in experimental models and are now being evaluated in clinical trials for the treatment of human spinal cord injury (SCI). To date, experimental evaluation of implanted cell survival, migration, and integration within the injured central nervous system (CNS) of animals has been technically demanding, requiring tissue sectioning, staining, imaging, and manual reconstruction of 2-dimensional (2D) specimens in 3 dimensions (3D). Not only are these histological procedures laborious and fraught with processing artifacts during manual 3D reconstruction, but they are time-intensive. Herein we describe the utility of 3D ultramicroscopy for assessment of cell therapies after SCI, a new state-of-the-art imaging modality in which whole brain and spinal cord samples are optically sectioned to allow evaluation of intact, macroscopic specimens with microscopic resolution.

Entities:  

Keywords:  3D ultramicroscopy; Schwann cells; cell therapy; spinal cord injury

Year:  2012        PMID: 23459000      PMCID: PMC3584749          DOI: 10.1310/sci1801-73

Source DB:  PubMed          Journal:  Top Spinal Cord Inj Rehabil        ISSN: 1082-0744


  15 in total

Review 1.  Grafting of genetically modified fibroblasts into the injured spinal cord.

Authors:  Y Liu; M Murray; A Tessler; I Fischer
Journal:  Prog Brain Res       Date:  2000       Impact factor: 2.453

Review 2.  False resurrections: distinguishing regenerated from spared axons in the injured central nervous system.

Authors:  Oswald Steward; Binhai Zheng; Marc Tessier-Lavigne
Journal:  J Comp Neurol       Date:  2003-04-21       Impact factor: 3.215

Review 3.  Transplantation strategies to promote repair of the injured spinal cord.

Authors:  Mary Bartlett Bunge; Damien D Pearse
Journal:  J Rehabil Res Dev       Date:  2003 Jul-Aug

Review 4.  Designing cell- and gene-based regeneration strategies to repair the injured spinal cord.

Authors:  D D Pearse; M B Bunge
Journal:  J Neurotrauma       Date:  2006 Mar-Apr       Impact factor: 5.269

5.  Recovery of function following grafting of human bone marrow-derived stromal cells into the injured spinal cord.

Authors:  B Timothy Himes; Birgit Neuhuber; Carl Coleman; Robert Kushner; Sharon A Swanger; Gene C Kopen; Joseph Wagner; Jed S Shumsky; Itzhak Fischer
Journal:  Neurorehabil Neural Repair       Date:  2006-06       Impact factor: 3.919

Review 6.  Regeneration in the peripheral nervous system.

Authors:  S M Hall
Journal:  Neuropathol Appl Neurobiol       Date:  1989 Nov-Dec       Impact factor: 8.090

7.  Survival, integration, and axon growth support of glia transplanted into the chronically contused spinal cord.

Authors:  D J Barakat; S M Gaglani; S R Neravetla; A R Sanchez; C M Andrade; Y Pressman; R Puzis; M S Garg; M B Bunge; D D Pearse
Journal:  Cell Transplant       Date:  2005       Impact factor: 4.064

8.  Transplantation of Schwann cells and olfactory ensheathing glia after spinal cord injury: does pretreatment with methylprednisolone and interleukin-10 enhance recovery?

Authors:  Damien Daniel Pearse; Alexander Eduardo Marcillo; Martin Oudega; Michael Paul Lynch; Patrick McGhee Wood; Mary Bartlett Bunge
Journal:  J Neurotrauma       Date:  2004-09       Impact factor: 5.269

9.  cAMP and Schwann cells promote axonal growth and functional recovery after spinal cord injury.

Authors:  Damien D Pearse; Francisco C Pereira; Alexander E Marcillo; Margaret L Bates; Yerko A Berrocal; Marie T Filbin; Mary Bartlett Bunge
Journal:  Nat Med       Date:  2004-05-23       Impact factor: 53.440

10.  Schwann cell but not olfactory ensheathing glia transplants improve hindlimb locomotor performance in the moderately contused adult rat thoracic spinal cord.

Authors:  Toshihiro Takami; Martin Oudega; Margaret L Bates; Patrick M Wood; Naomi Kleitman; Mary Bartlett Bunge
Journal:  J Neurosci       Date:  2002-08-01       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.